(D-Ser(2))Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

Barry D. Kerr, Peter Flatt, Victor Gault

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Oxyntomodulin (Oxm) is a hormone which has been shown to exhibit a range of potentially beneficial actions for alleviation of obesity-diabetes However, exploitation of Oxm-based therapies has been severely restricted due to degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, the aim of this study was to assess the glucose-lowering, insulin-releasing and anorexigenic actions of chemically modified, enzyme-resistant analogues of Oxm Oxm, (D-Ser(2))Oxm and (D-Ser(2))Oxm[mPEG-PAL], were incubated with DPP-IV to assess enzyme stability and pancreatic beta-cells to evaluate insulin secretion. cAMP production was assessed using glucagon-like peptide-1 (GLP-1) and glucagon receptor transfected cells. In vivo effects of Oxm analogues on glucose homeostasis, insulin secretion, food Intake and bodyweight were examined in obese diabetic (ob/ob) mice. (D-Ser(2))Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (D-Ser(2))Oxm and Oxm. All peptides demonstrated similar in vitro cAMP and insulin-releasing actions, which was associated with dual action at GLP-1 and glucagon receptors Acute administration of (D-Ser(2))Oxm[mPEG-PAL] and (D-Ser(2))Oxm reduced plasma glucose and food intake, whilst plasma insulin levels were elevated. Once-daily administration of (D-Ser(2))Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and increased plasma insulin. Furthermore, daily (D-Ser(2))Oxm[mPEG-PAL] improved glucose tolerance, increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin and triglyceride levels. The ability of enzyme-resistant (D-Ser(2))Oxm[mPEG-PAL] to improve glucose homeostasis, insulin secretion, satiety, bodyweight and markers of fat metabolism suggests significant promise for Oxm-based therapies for obesity-diabetes. (C) 2010 Elsevier Inc All rights reserved
LanguageEnglish
Pages1727-1735
JournalBIiochemical Pharmacology
Volume80
Issue number11
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Oxyntomodulin
Hypoglycemic Agents
Insulin
Glucose
Glucagon Receptors
Eating
4 alpha-glucanotransferase
Homeostasis
Obesity
Nicotinamide Phosphoribosyltransferase

Cite this

@article{b7a1c5a96d0f40c897f8e70024e97f51,
title = "(D-Ser(2))Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions",
abstract = "Oxyntomodulin (Oxm) is a hormone which has been shown to exhibit a range of potentially beneficial actions for alleviation of obesity-diabetes However, exploitation of Oxm-based therapies has been severely restricted due to degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, the aim of this study was to assess the glucose-lowering, insulin-releasing and anorexigenic actions of chemically modified, enzyme-resistant analogues of Oxm Oxm, (D-Ser(2))Oxm and (D-Ser(2))Oxm[mPEG-PAL], were incubated with DPP-IV to assess enzyme stability and pancreatic beta-cells to evaluate insulin secretion. cAMP production was assessed using glucagon-like peptide-1 (GLP-1) and glucagon receptor transfected cells. In vivo effects of Oxm analogues on glucose homeostasis, insulin secretion, food Intake and bodyweight were examined in obese diabetic (ob/ob) mice. (D-Ser(2))Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (D-Ser(2))Oxm and Oxm. All peptides demonstrated similar in vitro cAMP and insulin-releasing actions, which was associated with dual action at GLP-1 and glucagon receptors Acute administration of (D-Ser(2))Oxm[mPEG-PAL] and (D-Ser(2))Oxm reduced plasma glucose and food intake, whilst plasma insulin levels were elevated. Once-daily administration of (D-Ser(2))Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and increased plasma insulin. Furthermore, daily (D-Ser(2))Oxm[mPEG-PAL] improved glucose tolerance, increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin and triglyceride levels. The ability of enzyme-resistant (D-Ser(2))Oxm[mPEG-PAL] to improve glucose homeostasis, insulin secretion, satiety, bodyweight and markers of fat metabolism suggests significant promise for Oxm-based therapies for obesity-diabetes. (C) 2010 Elsevier Inc All rights reserved",
author = "Kerr, {Barry D.} and Peter Flatt and Victor Gault",
year = "2010",
month = "12",
doi = "10.1016/j.bcp.2010.08.010",
language = "English",
volume = "80",
pages = "1727--1735",
journal = "BIiochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - (D-Ser(2))Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

AU - Kerr, Barry D.

AU - Flatt, Peter

AU - Gault, Victor

PY - 2010/12

Y1 - 2010/12

N2 - Oxyntomodulin (Oxm) is a hormone which has been shown to exhibit a range of potentially beneficial actions for alleviation of obesity-diabetes However, exploitation of Oxm-based therapies has been severely restricted due to degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, the aim of this study was to assess the glucose-lowering, insulin-releasing and anorexigenic actions of chemically modified, enzyme-resistant analogues of Oxm Oxm, (D-Ser(2))Oxm and (D-Ser(2))Oxm[mPEG-PAL], were incubated with DPP-IV to assess enzyme stability and pancreatic beta-cells to evaluate insulin secretion. cAMP production was assessed using glucagon-like peptide-1 (GLP-1) and glucagon receptor transfected cells. In vivo effects of Oxm analogues on glucose homeostasis, insulin secretion, food Intake and bodyweight were examined in obese diabetic (ob/ob) mice. (D-Ser(2))Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (D-Ser(2))Oxm and Oxm. All peptides demonstrated similar in vitro cAMP and insulin-releasing actions, which was associated with dual action at GLP-1 and glucagon receptors Acute administration of (D-Ser(2))Oxm[mPEG-PAL] and (D-Ser(2))Oxm reduced plasma glucose and food intake, whilst plasma insulin levels were elevated. Once-daily administration of (D-Ser(2))Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and increased plasma insulin. Furthermore, daily (D-Ser(2))Oxm[mPEG-PAL] improved glucose tolerance, increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin and triglyceride levels. The ability of enzyme-resistant (D-Ser(2))Oxm[mPEG-PAL] to improve glucose homeostasis, insulin secretion, satiety, bodyweight and markers of fat metabolism suggests significant promise for Oxm-based therapies for obesity-diabetes. (C) 2010 Elsevier Inc All rights reserved

AB - Oxyntomodulin (Oxm) is a hormone which has been shown to exhibit a range of potentially beneficial actions for alleviation of obesity-diabetes However, exploitation of Oxm-based therapies has been severely restricted due to degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, the aim of this study was to assess the glucose-lowering, insulin-releasing and anorexigenic actions of chemically modified, enzyme-resistant analogues of Oxm Oxm, (D-Ser(2))Oxm and (D-Ser(2))Oxm[mPEG-PAL], were incubated with DPP-IV to assess enzyme stability and pancreatic beta-cells to evaluate insulin secretion. cAMP production was assessed using glucagon-like peptide-1 (GLP-1) and glucagon receptor transfected cells. In vivo effects of Oxm analogues on glucose homeostasis, insulin secretion, food Intake and bodyweight were examined in obese diabetic (ob/ob) mice. (D-Ser(2))Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (D-Ser(2))Oxm and Oxm. All peptides demonstrated similar in vitro cAMP and insulin-releasing actions, which was associated with dual action at GLP-1 and glucagon receptors Acute administration of (D-Ser(2))Oxm[mPEG-PAL] and (D-Ser(2))Oxm reduced plasma glucose and food intake, whilst plasma insulin levels were elevated. Once-daily administration of (D-Ser(2))Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and increased plasma insulin. Furthermore, daily (D-Ser(2))Oxm[mPEG-PAL] improved glucose tolerance, increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin and triglyceride levels. The ability of enzyme-resistant (D-Ser(2))Oxm[mPEG-PAL] to improve glucose homeostasis, insulin secretion, satiety, bodyweight and markers of fat metabolism suggests significant promise for Oxm-based therapies for obesity-diabetes. (C) 2010 Elsevier Inc All rights reserved

U2 - 10.1016/j.bcp.2010.08.010

DO - 10.1016/j.bcp.2010.08.010

M3 - Article

VL - 80

SP - 1727

EP - 1735

JO - BIiochemical Pharmacology

T2 - BIiochemical Pharmacology

JF - BIiochemical Pharmacology

SN - 0006-2952

IS - 11

ER -